1SEYMOUR DG,BALL AE,RUSSELL EM,et al. Problems in using health survey questionnaires in older patients with physical disabilities.The reliability and validity of the SF-36 and the effect of cognitive impairment[J].J Eval Clin Pract,2001,7(4):411.
2HOBART JC,LAMPING DL,FREEMAN JA,et al. Evidence based measurement:which disability scale for neurologic rehabilitation[J].Neurology,2001,57(4):639.
3KUCUKDEVECI AA,YAVUZER G,ELHAN AH,et al. Adaptation of the Functional Independence Measure for use in Turkey[J].Clin Rehabil,2001,15(3):311.
4DAVING Y,ANDREN E,NORDHOLM L,et al. Reliability of an interview approach to the Functional Independence Measure[J].Clin Rehabil,2001,15(3):301.
5COHEN ME,MARINO RJ. The tools of disability outcomes research functional status measures[J].Arch Phys Med Rehabil,2000,81(12):21.
6SCHINDL MR,FORSTNER C,KERN H,et al. Evaluation of a German version of the Rivermead Mobility Index (RMI) in acute and chronic stroke patients[J].Eur J Neurol,2000,7(5):523.
6Schror K. The pharmacology of cilostazol. Diabetes Obes Metab 2002; 4(Suppl 2)S14 -9
7Dyck PJ. Detection, characterization. and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988; 11 ( 1 ): 21 - 32
8Hafer-Macko CE, Ivey FM, Gyure KA, et al. Thrombomodulin deficiency in human diabetic nerve microvaseulature. Diabetes 2002; 51 (6): 1957 -63
9Suh KS, Oh SJ, Woo JT, et al. Effect of cilostazol on the neuropathies of streptozotocin-induced diabetic rats. Korean J Inter Med 1999; 14(2): 34 -40
10Yashiro Y, Ohhashi T. Effects of cilostazol, a selective cycle AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles. Jpn J Physiol 2002; 52 (5): 471 - 7
